By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Soligenix 

29 Emmons Drive
Suite C-10
Princeton  New Jersey  08540  U.S.A.
Phone: 609-538-8200 Fax: 609-452-6467


SEARCH JOBS








Company News
Soligenix (SNGX) Announces Positive Recommendation By Data Review Committee On Its Phase 2 Clinical Trial Of SGX942 For The Treatment Of Oral Mucositis In Head And Neck Cancer Patients 3/3/2015 6:39:25 AM
Soligenix (SNGX) Release: Ricin Toxin Vaccine Poster Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC 2/13/2015 8:02:53 AM
12635 E. Montview Blvd. Release: Preclinical Melioidosis Results Presented At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC 2/11/2015 10:38:44 AM
Soligenix (SNGX) To Present At The 17th Annual BIO CEO & Investor Conference In New York City 2/5/2015 12:13:46 PM
Soligenix (SNGX) Announces Presentation And Poster At The 2015 ASM Biodefense And Emerging Diseases Research Meeting In Washington, DC 2/2/2015 12:42:58 PM
Soligenix (SNGX) Announces Publication Successfully Demonstrating Enhanced Immunogenicity Of Its Heat-Stable Anthrax Vaccine 1/29/2015 8:00:08 AM
FDA Grants Soligenix (SNGX) "Fast Track" Designation For SGX301 For The First-Line Treatment Of Cutaneous T-Cell Lymphoma 1/7/2015 7:34:09 AM
Soligenix (SNGX) Announces Positive Preliminary Nonclinical Results In Macrophage Activation Syndrome 1/5/2015 7:30:45 AM
Soligenix (SNGX) Announces Publication of Combination Ricin/Anthrax Vaccine Data 12/29/2014 7:38:51 AM
Soligenix (SNGX) Announces Closing Of Public Offering Of Units 12/24/2014 9:57:58 AM
12345678910...
//-->